Pear Therapeutics, Inc. (PEAR)

Market Cap	42.19M
Revenue (ttm)	11.45M
Net Income (ttm)	-30.37M
Shares Out	145.57M
EPS (ttm)	6.39
PE Ratio	0.05
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,755,618
Open	0.264
Previous Close	0.250
Day's Range	0.254 - 0.350
52-Week Range	0.200 - 6.740
Beta	n/a
Analysts	Buy
Price Target	5.25 (+1,711.59%)
Earnings Date	May 15, 2023

About PEAR

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, suc...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2013
• Employees: 260
• Stock Exchange: NASDAQ
• Ticker Symbol: PEAR

Financial Performance

In 2021, PEAR's revenue was $4.21 million, a decrease of -55.16% compared to the previous year's $9.38 million. Losses were -$65.14 million, -39.73% less than in 2020.

Analyst Forecast

According to 14 analysts, the average rating for PEAR stock is "Buy." The 12-month stock price forecast is $5.25, which is an increase of 1,711.59% from the latest price.

Price Target

$5.25

(1,711.59% upside)

Analyst Consensus: Buy